{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:13Z","timestamp":1787008753680,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/19\/49\/34541"],"award-info":[{"award-number":["FS\/19\/49\/34541"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022572","name":"Sheffield Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203321"],"award-info":[{"award-number":["NIHR203321"]}],"id":[{"id":"10.13039\/501100022572","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study explored relationships between fibrin clot lysis time at randomization and clinical outcomes in patients with AF enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Plasma samples were obtained from anticoagulation-na\u00efve participants, before initiation of study medication (n = 1841). Fibrin clot turbidimetry was performed, and lysis time determined. Associations between lysis time and characteristics, biomarkers, and on-treatment bleeding and cardiovascular events were assessed by lysis time quartile (Q1-4, shortest to longest).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A shorter lysis time was associated with being older, male, permanent AF, lower body mass index, estimated glomerular filtration rate and C-reactive protein, and higher N-terminal pro-B-type natriuretic peptide. Major and clinically relevant non-major bleeding was significantly more frequent in lysis time Q1 vs. Q4 [6.3%\/yr vs. 2.1%\/yr; HR, 2.99 (95% CI, 1.75\u20135.12); P = .001], including after multifactorial adjustment [HR, 2.61 (1.45\u20134.69); P = .016]. Those in Q2 and Q3 had intermediate bleeding risk vs. Q4 [HR, 2.21 (1.27\u20133.87); 2.08 (1.18\u20133.66) respectively], suggesting a graduated effect. Treatment allocation to apixaban vs. warfarin did not affect the relationship between lysis time and bleeding (interaction-P = .80). There was no significant association between lysis time and a composite of cardiovascular death, stroke, systemic embolism or myocardial infarction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Shorter pre-treatment fibrin clot lysis time independently predicted higher bleeding risk in patients receiving oral anticoagulation for AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf347","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T07:59:16Z","timestamp":1746518356000},"page":"1949-1960","source":"Crossref","is-referenced-by-count":7,"title":["Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-8852","authenticated-orcid":false,"given":"William A E","family":"Parker","sequence":"first","affiliation":[{"name":"Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield , Beech Hill Road, Sheffield S10 2RX ,","place":["UK"]},{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Glossop Road, Sheffield S10 2JF ,","place":["UK"]},{"name":"South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Herries Road, Sheffield S5 7AU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Nelson","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield , Beech Hill Road, Sheffield S10 2RX ,","place":["UK"]},{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Glossop Road, Sheffield S10 2JF ,","place":["UK"]},{"name":"South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Herries Road, Sheffield S5 7AU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lee","sequence":"additional","affiliation":[{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Glossop Road, Sheffield S10 2JF ,","place":["UK"]},{"name":"South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Herries Road, Sheffield S5 7AU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M","family":"Judge","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield , Beech Hill Road, Sheffield S10 2RX ,","place":["UK"]},{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Glossop Road, Sheffield S10 2JF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-3725","authenticated-orcid":false,"given":"Ramzi A","family":"Ajjan","sequence":"additional","affiliation":[{"name":"LIGHT laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Clarendon Way, Leeds LS2 3AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-6045","authenticated-orcid":false,"given":"Johan","family":"Westerbergh","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , Dag Hammarskj\u00f6lds V\u00e4g, 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-5671","authenticated-orcid":false,"given":"Agneta","family":"Siegbahn","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-8084","authenticated-orcid":false,"given":"Christina","family":"Christersson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-2462","authenticated-orcid":false,"given":"John H","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Duke University , W Morgan St, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Duke University , W Morgan St, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-3291","authenticated-orcid":false,"given":"Christopher B","family":"Granger","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Duke University , W Morgan St, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8263-8304","authenticated-orcid":false,"given":"Elaine M","family":"Hylek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston University School of Medicine , East Concord St, Boston, MA 02118 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-6531","authenticated-orcid":false,"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , Dag Hammarskj\u00f6lds V\u00e4g, 751 85 Uppsala ,","place":["Sweden"]},{"name":"Department of Medical Sciences, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield , Beech Hill Road, Sheffield S10 2RX ,","place":["UK"]},{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Glossop Road, Sheffield S10 2JF ,","place":["UK"]},{"name":"South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Herries Road, Sheffield S5 7AU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2026042119591037000_ehaf347-B1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2026042119591037000_ehaf347-B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14779072.2023.2160319","article-title":"Atrial fibrillation and stroke","volume":"21","author":"Choi","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026042119591037000_ehaf347-B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/eurheartj\/ehw119","article-title":"Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation","volume":"38","author":"Spronk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026042119591037000_ehaf347-B4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026042119591037000_ehaf347-B5","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/europace\/euac020","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: a position paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society","volume":"24","author":"Gorog","year":"2022","journal-title":"Europace"},{"key":"2026042119591037000_ehaf347-B6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026042119591037000_ehaf347-B7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026042119591037000_ehaf347-B8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/1479164110383723","article-title":"Coagulation and fibrinolysis in diabetes","volume":"7","author":"Alzahrani","year":"2010","journal-title":"Diab Vasc Dis Res"},{"key":"2026042119591037000_ehaf347-B9","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026042119591037000_ehaf347-B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"Farag","year":"2019","journal-title":"Eur Heart J"},{"key":"2026042119591037000_ehaf347-B11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur Heart J"},{"key":"2026042119591037000_ehaf347-B12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/heartjnl-2018-313351","article-title":"Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation","volume":"105","author":"Christersson","year":"2019","journal-title":"Heart"},{"key":"2026042119591037000_ehaf347-B13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"2026042119591037000_ehaf347-B14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026042119591037000_ehaf347-B15","doi-asserted-by":"publisher","first-page":"e018984","DOI":"10.1161\/JAHA.120.018984","article-title":"Screening of multiple biomarkers associated with ischemic stroke in atrial fibrillation","volume":"9","author":"Hijazi","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026042119591037000_ehaf347-B16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1055\/s-0039-1701011","article-title":"Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study","volume":"120","author":"Sumaya","year":"2020","journal-title":"Thromb Haemost"},{"key":"2026042119591037000_ehaf347-B17","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"2026042119591037000_ehaf347-B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcms.2016.10.001","article-title":"Topical application of tranexamic acid in anticoagulated patients undergoing minor oral surgery: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"de Vasconcellos","year":"2017","journal-title":"J Craniomaxillofac Surg"},{"key":"2026042119591037000_ehaf347-B19","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehad088","article-title":"Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction","volume":"44","author":"Lee","year":"2023","journal-title":"Eur Heart J"},{"key":"2026042119591037000_ehaf347-B20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrcardio.2011.91","article-title":"Arterial thrombus formation in cardiovascular disease","volume":"8","author":"Lippi","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026042119591037000_ehaf347-B21","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1001\/archinte.163.20.2534-a","article-title":"Red vs white thrombi: treating the right clot is crucial","volume":"163","author":"Tan","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026042119591037000_ehaf347-B22","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","article-title":"Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model","volume":"35","author":"Thomas","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026042119591037000_ehaf347-B23","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.114.011204","article-title":"Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"130","author":"Wallentin","year":"2014","journal-title":"Circulation"},{"key":"2026042119591037000_ehaf347-B24","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacc.2012.04.063","article-title":"Inflammation in atrial fibrillation","volume":"60","author":"Guo","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026042119591037000_ehaf347-B25","doi-asserted-by":"publisher","first-page":"e000908","DOI":"10.1136\/openhrt-2018-000908","article-title":"Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial","volume":"5","author":"Sandhu","year":"2018","journal-title":"Open Heart"},{"key":"2026042119591037000_ehaf347-B26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11239-023-02837-3","article-title":"Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme","volume":"56","author":"Garabon","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2026042119591037000_ehaf347-B27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jth.12102","article-title":"Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis","volume":"11","author":"Incampo","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2026042119591037000_ehaf347-B28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cjca.2019.08.001","article-title":"Clot lysis time predicts stroke during anticoagulant therapy in patients with atrial fibrillation","volume":"36","author":"Drabik","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026042119591037000_ehaf347-B29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/cvr\/cvad017","article-title":"Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice","volume":"119","author":"Z\u0105bczyk","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026042119591037000_ehaf347-B30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1161\/ATVBAHA.109.183707","article-title":"Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system","volume":"29","author":"Ajjan","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/16\/1949\/63405590\/ehaf347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/16\/1949\/63405590\/ehaf347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:59:17Z","timestamp":1776815957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/16\/1949\/8153716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":30,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf347","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,21]]},"published":{"date-parts":[[2025,5,30]]}}}